Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

61.62 +0.08 (+0.13%)

Delayed Quote Updated: 10:08 AM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

15 16 Next >

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

November 28, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference

November 21, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results

November 16, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

November 13, 2023

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Analyst Expectations for Arrowhead Pharma's Future ↗

September 19, 2023

Via Benzinga

Analyst Ratings for Arrowhead Pharma ↗

August 08, 2023

Via Benzinga

Analyst Expectations for Arrowhead Pharma's Future ↗

July 21, 2023

Via Benzinga

Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference

November 06, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023

November 02, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Johnson & Johnson Offloads Rights For Hepatitis B Candidate To GSK ↗

October 31, 2023

GSK plc (NYSE: GSK) and Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) have

Via Benzinga

Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences

October 03, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Expert Ratings for Arrowhead Pharma ↗

June 30, 2023

Via Benzinga

Where Arrowhead Pharma Stands With Analysts ↗

May 24, 2023

Via Benzinga

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

September 27, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023 ↗

September 19, 2023

Via Benzinga

Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023

September 11, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Cramer Says 'Please Stay Away' From This EV Maker, It 'Should Not Be Public' ↗

September 08, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Norfolk Southern Corporation (NYSE: NSC) is the "cheapest I’ve seen in a very long time,

Via Benzinga

Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences

September 01, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results

August 07, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results

July 24, 2023

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023 ↗

July 21, 2023

Via Benzinga

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy

July 17, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 06, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1

June 27, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease

June 24, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million ↗

June 15, 2023

Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A.

Via Investor's Business Daily

Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences

June 06, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics

June 01, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead CEO Christopher Anzalone Addresses The 'Really Important Event' In Lung Disease ↗

June 01, 2023

Arrowhead CEO Christopher Anzalone discusses expectations for ARO-RAGE in lung disease.

Via Investor's Business Daily

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.